Secretive Theracos seeks niche in SGLT2 class
This article was originally published in Scrip
Executive Summary
With two SGLT2 inhibitors approved in the US and a third that may be able to overcome its recent US FDA rejection, it remains to be seen whether the type 2 diabetes market needs another drug in that class, but privately-held Theracos believes it has a differentiated product candidate that could overcome certain side effects.